论文部分内容阅读
目的:探讨慢性充血性心力衰竭(CHF)患者在常规加用依拉普利治疗基础上联合安体舒通治疗对血浆脑钠肽(BNP)的影响。方法:将CHF患者68例随机分为两组:依拉普利组35例,依拉普利加安体舒通组33例,治疗观察时间均为24周。检测治疗前后两组患者的血压、血浆BNP水平、超声心动图等。结果:治疗24周后,两组患者血浆BNP水平、超声心动图与治疗前比较有统计学意义(P<0.05)。治疗后两组间血浆BNP水平比较有统计学意义(P<0.01)。结论:依拉普利与安体舒通均能改善患者心功能、降低血浆BNP水平,两药联合治疗更明显。
Objective: To investigate the effect of spironolactone on plasma brain natriuretic peptide (BNP) in patients with chronic congestive heart failure (CHF) on the basis of routine treatment with enalapril. Methods: Sixty-eight CHF patients were randomly divided into two groups: 35 in the enalapril group and 33 in the group of enalapril plus spironolactone. The treatment time was 24 weeks. Blood pressure, plasma BNP level and echocardiography were measured before and after treatment. Results: Plasma BNP level and echocardiography were significantly different between two groups after treatment for 24 weeks (P <0.05). After treatment, plasma BNP levels between the two groups were statistically significant (P <0.01). Conclusion: Both enalapril and spironolactone can improve cardiac function, reduce plasma BNP levels, the two drugs combined treatment is more obvious.